Orchid Pharma (Orchid) and Pharmasyntez JSC (Pharmasyntez) have entered into a licensing and supply agreement for Exblifep (cefepime/enmetazobactam), a novel combination antibiotic for the treatment of complicated urinary tract infections (cUTI) and hospital-acquired and ventilator-associated bacterial pneumonia (HAP/VAP) caused by Gramnegative bacterial pathogens, subject to regulatory approval by the Ministry of Health of the Russian Federation.
Exblifep is a carbapenem-sparing antibiotic developed to address the growing clinical challenge posed by ESBL-producing Gram-negative bacteria in serious hospital infections. The product is approved by the U.S. Food and Drug Administration (USFDA) and the European Medicines Agency (EMA), is included in IDSA and EUCAST treatment guidelines, and is the first new chemical entity originating from an Indian pharmaceutical company to receive both approvals.
Under the agreement, Pharmasyntez will hold the exclusive rights to register and commercialize Exblifep in Russia, with Orchid supplying the finished dosage form. The partnership represents a potential opportunity of around $178 million over the first 10 years, reflecting the scale of unmet clinical need and the significant hospital procurement volumes in the Russian market.
Orchid Pharma, established as an export-oriented unit (EOU), is a vertically integrated company spanning the entire pharmaceutical value chain from discovery to delivery with established credentials in research, manufacturing and marketing.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1950.00 |
| Dr. Reddys Labs. | 1223.90 |
| Cipla | 1429.45 |
| Lupin | 2500.05 |
| Zydus Lifesciences | 1153.50 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: